Achieve Life Sciences

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Achieve Life Sciences reports positive Q4 results, eyes regulatory milestones

Achieve Life Sciences demonstrated strong performance in Q4 2022 with positive trial results and strategic advancements. While facing financial challenges, the company's focus on innovation and upcoming milestones positions it well for growth and regulatory success.

Achieve Life Sciences reports positive trial results, faces funding challenges

Achieve Life Sciences demonstrated promising results in vaping cessation with cytisinicline treatment, showing significant benefits and a strong market demand for cessation solutions.
While facing challenges of increasing expenses and a net loss in Q1 2023, the company's cash balance and upcoming trials provide opportunities for growth and market expansion.
The company's strategic initiatives, including the Board of Directors refresh, position Achieve Life Sciences for future success in addressing the vaping cessation market.

Achieve Life Sciences advances cytisinicline trials, targets FDA approval

Achieve Life Sciences is making significant progress with cytisinicline, despite facing financial losses. Strategic initiatives and a proactive approach to FDA engagement position the company well for future growth and NDA submission.

Achieve Life Sciences reports improved Q3 performance and eyes NDA submission

Achieve Life Sciences shows financial improvement and promising results in the cytisinicline program for smoking cessation. Engaging with the FDA for NDA submission and seeking commercial partners are key priorities. Challenges include finalizing partnerships and defining regulatory pathways, while opportunities exist in global partnerships and public health impact.

Achieve Life Sciences excels in 2023, poised for growth and innovation

Achieve Life Sciences demonstrated strong performance in achieving key milestones, securing financing, and presenting positive trial results in 2023.
While facing challenges in regulatory discussions and trial completion, the company's strategic strengths in financial stability, regulatory compliance, and innovation position it well for future growth.
Opportunities lie in market expansion, partnerships, and visibility enhancement through continued FDA engagement, commercial collaborations, and industry participation.

Achieve Life Sciences excels in trials and secures funding for growth

Achieve Life Sciences demonstrated strong operational and financial performance with positive trial outcomes and strategic financing.
Regulatory advancements and successful trial results underscore the company's credibility and potential for market expansion.
Challenges in recruitment, regulatory compliance, and financial management require attention for sustained growth and success.

Achieve Life Sciences advances vaping cessation program with FDA breakthrough

Achieve Life Sciences showcased progress in its Cytisinicline Development Program and financial stability through debt refinancing.
While facing challenges in trial enrollment and regulatory requirements, the company remains optimistic about future milestones.
The FDA breakthrough therapy designation and focus on public health underscore Achieve Life Sciences' commitment to addressing nicotine dependence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement in quit rates and robust safety profile. Phase 3 ORCA-3 registration trial is ongoing, and we expect the data readout in 2Q 2023; we expect the results to be positive.

Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug

SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development.

Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation

Amprius Technologies Inc

Bilibili

Champions Oncology

Digimarc

Gannett Co.

KalVista Pharma

KLX Energy Services Holdings Inc

System1, Inc

Unity Biotechnology Inc

With the significant volatility and uncertainty in equity markets expected to continue through 2023, some investors are seeking alternative short to medium-term trading ideas.

Fintel's top 10 Gamma Squeeze Stocks For November

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Nicole Jones - Investor Relations-CG Capital John Bencich - Chief Executive Officer Jerry Wan - Principal Accounting Officer Cindy Jacobs - President & Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital François Brisebois - Oppenheimer Michael Higgins - Ladenburg Thalmann John Vandermosten - Zacks Jim Molloy - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to Achieve Life Sciences Third Quarter 2022 Earnings Conference Call. All lines have been placed on a listen-only mode.

Achieve Life Sciences, Inc. (ACHV) Q3 2022 Earnings Call Transcript

SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its third quarter financial results and provide an update on the cytisinicline development program on Monday, November 14, 2022, at 4:30 PM EST.

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022

ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer John Bencich - Chief Executive Officer Conference Call Participants Michael Higgins - Ladenburg Thalmann François Brisebois - Oppenheimer John Vandermosten - Zacks Vernon Bernardino - H.C. Wainwright Jim Molloy - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to the Achieve Life Science Second Quarter 2022 Earnings Conference Call.

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2022 Results - Earnings Call Transcript

Company to host conference call at 4:30 PM EDT today, August 11, 2022 Company to host conference call at 4:30 PM EDT today, August 11, 2022

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program on Thursday, August 11, 2022, at 4:30 PM EDT.

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

SEATTLE and VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued inducement grants of stock options to two new employees.

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the H.C. Wainwright 1st Annual Mental Health Conference. The conference is taking place in-person at the Lotte New York Palace Hotel and virtually on June 27, 2022. Details to access the presentation are as follows:

Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference

SEATTLE and VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the LD Micro Invitational Conference. The Conference is taking place in-person at the Four Seasons in Westlake Village, CA from June 7 - 9, 2022. Details to access the presentation are as follows:

Achieve Life Sciences Announces Participation at LD Micro Invitational Conference

SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the Spring Into Action Best Ideas Virtual Investor Conference. The conference is taking place virtually from May 16 - 20, 2022. Details for access to the presentation are as follows:

Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Bencich - CEO & Director Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Michael Higgins - Ladenburg Thalmann & Co. John Vandermosten - Zacks Small-Cap Research Operator Good day, and thank you for standing by. Welcome to the Achieve Life Sciences First Quarter 2022 Earnings Conference Call.

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript

Company to host conference call at 4:30 PM EDT today, May 12, 2022 Company to host conference call at 4:30 PM EDT today, May 12, 2022

Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update

Achieve Life Sciences Inc (NASDAQ: ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers.  The 6- and 12-week cytisinicline treatments demonstrated significantly better.

Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation

SEATTLE and VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its first quarter financial results and provide an update on the cytisinicline development program on Thursday, May 12, 2022, at 4:30 PM EDT. To access the webcast, please use the following link 1Q22 Earnings Webcast . Alternatively, you may access the live conference call by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 3887417. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days.

Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022

We are initiating ACHV with a buy rating and a target price of USD 70.

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

SEATTLE and VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Vaughn Himes to the company's Board of Directors, effective immediately.

Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors

SEATTLE and VANCOUVER, British Columbia, March 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Manufacturing and Quality Operations Team with the hiring of a Vice President of Process Control and Quality Assurance.

Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript

Company to host conference call at 4:30 PM EST today, March 10, 2022 Company to host conference call at 4:30 PM EST today, March 10, 2022

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update

SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in the Oppenheimer 32nd Annual Virtual Healthcare Conference and the Maxim 2022 Virtual Growth Conference.

Achieve Life Sciences Announces Participation in March Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in the Winter Wonderland Best Ideas Virtual Investor Conference and Aegis Virtual Conference during February 2022.

Achieve Life Sciences Announces Participation in February Investor Conferences

Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cytisinicline dosed three times daily compared to placebo in 750 adult smokers.

News for Achieve Life Sciences Stock (ACHV)